APPG Chair Nic Dakin writes to Health Secretary to urge him to overturn decision
to remove Abraxane from CDF
Joint letter from the APPG on Pancreatic Cancer, Pancreatic Cancer Action and Pancreatic Cancer UK sets out why pancreatic cancer drug Abraxane should remain on the Cancer Drugs Fund list
On 14th September APPG Chair Nic Dakin wrote to the Secretary of State for Health Jeremy Hunt urging him to reverse the decision to remove Abraxane from the Cancer Drugs Fund.
NHS England announced on 4th September that the life-extending drug would no longer be available to pancreatic cancer patients through the Cancer Drugs Fund from 4 November 2015. The move will leave hundreds of patients in England with no way of accessing the drug for free. This will result in an inequality of treatment across Britain with patients in Scotland and Wales able to access the drug for free, whilst patients in England cannot.
When used in combination with standard chemotherapy, Abraxane can allow eligible patients with advanced pancreatic cancer to live an extra two months on average, and sometimes much longer. It is one of very few treatments for advanced pancreatic cancer in 20 years, and was the only pancreatic cancer drug on the CDF list of approved drugs.
The letter calls on the Secretary of State to intervene to ensure Abraxane remains available to pancreatic cancer patients in England.
Read the letter here: PCA Pancreatic Cancer UK and APPG Chair letter 14 09 15